文献速递肝病

肠道IL-33通过双重调控HIF-1α促进菌群来源氧化三甲胺合成并驱动代谢功能障碍相关脂肪性肝病进展

Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α.
PubMed 文献 · Hepatology · 2024-07-10

在人类和小鼠MASLD中,肝内IL-33及其受体ST2表达无显著变化,但人血清可溶性ST2及小鼠肠道IL-33和ST2表达显著升高。小鼠全局或肠道IL-33缺失可减轻MASLD相关代谢紊乱、炎症和纤维化,减少产氧化三甲胺菌群,改善肠屏障。IL-33通过核内结合HIF-1α抑制其激活并直接损伤肠屏障,胞外IL-33经ST2-Hif1a-Tbx21轴促进Th1分化,双重调控加重MASLD。

要点

  • MASLD时肝内IL-33/ST2无显著变化,而人血清可溶性ST2及小鼠肠道IL-33/ST2显著升高。
  • 小鼠全局或肠道IL-33缺失减轻MASLD相关代谢紊乱、炎症和纤维化,并减少产氧化三甲胺菌群。
  • IL-33通过核内抑制HIF-1α激活损伤肠屏障、胞外经ST2-Hif1a-Tbx21轴促Th1分化,双重调控加重MASLD。

核心结论

  • 肠道IL-33通过双重调控HIF-1α促进菌群来源氧化三甲胺合成并加重MASLD进展。
  • 靶向IL-33及其相关菌群可能为MASLD管理提供潜在治疗策略。

研究设计与样本

  • 研究在人类和小鼠MASLD中检测IL-33/ST2表达,并使用全局或肠道IL-33缺失小鼠、ST2敲除小鼠及菌群移植实验。

主要发现

  • 人类和小鼠MASLD肝内IL-33及ST2表达较对照无显著变化,而人血清可溶性ST2及小鼠肠道IL-33和ST2表达在MASLD中显著升高。
  • 小鼠全局或肠道IL-33缺失通过降低肠屏障通透性和纠正肠道菌群失调,减轻MASLD相关代谢紊乱、炎症和纤维化。
  • 将IL-33缺陷小鼠肠道菌群移植给野生型小鼠可预防MASLD进展。
  • IL-33缺失导致产氧化三甲胺细菌丰度降低;用3,3-二甲基-1-丁醇抑制氧化三甲胺合成可减轻MASLD小鼠肝脏氧化应激。
  • 核内IL-33结合缺氧诱导因子-1α并抑制其激活,直接损伤肠屏障完整性;胞外IL-33破坏肠道Th1/Th17平衡并经ST2-Hif1a-Tbx21轴促进Th1分化。

临床怎么用

  • 原文结论提出靶向IL-33及其相关菌群可能为MASLD管理提供潜在治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Gut microbiota plays a prominent role in the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). IL-33 is highly expressed at mucosal barrier sites and regulates intestinal homeostasis. Herein, we aimed to investigate the role and mechanism of intestinal IL-33 in MASLD. APPROACH AND RESULTS: In both humans and mice with MASLD, hepatic expression of IL-33 and its receptor suppression of tumorigenicity 2 (ST2) showed no significant change compared to controls, while serum soluble ST2 levels in humans, as well as intestinal IL-33 and ST2 expression in mice were significantly increased in MASLD. Deletion of global or intestinal IL-33 in mice alleviated metabolic disorders, inflammation, and fibrosis associated with MASLD by reducing intestinal barrier permeability and rectifying gut microbiota dysbiosis. Transplantation of gut microbiota from IL-33 deficiency mice prevented MASLD progression in wild-type mice. Moreover, IL-33 deficiency resulted in a decrease in the abundance of trimethylamine N -oxide-producing bacteria. Inhibition of trimethylamine N -oxide synthesis by 3,3-dimethyl-1-butanol mitigated hepatic oxidative stress in mice with MASLD. Nuclear IL-33 bound to hypoxia-inducible factor-1α and suppressed its activation, directly damaging the integrity of the intestinal barrier. Extracellular IL-33 destroyed the balance of intestinal Th1/Th17 and facilitated Th1 differentiation through the ST2- Hif1a - Tbx21 axis. Knockout of ST2 resulted in a diminished MASLD phenotype resembling that observed in IL-33 deficiency mice. CONCLUSIONS: Intestinal IL-33 enhanced gut microbiota-derived trimethylamine N -oxide synthesis and aggravated MASLD progression through dual regulation on hypoxia-inducible factor-1α. Targeting IL-33 and its associated microbiota may provide a potential therapeutic strategy for managing MASLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Hai S, Li X, Xie E, et al. Intestinal IL-33 promotes microbiota-derived trimethylamine N -oxide synthesis and drives metabolic dysfunction-associated steatotic liver disease progression by exerting dual regulation on HIF-1α. Hepatology. 2024. PMID: 38985971. doi:10.1097/HEP.0000000000000985

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。